NeuroPace (NASDAQ:NPCE) CEO Joel Becker Acquires 11,891 Shares of Stock

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) CEO Joel Becker bought 11,891 shares of the firm’s stock in a transaction on Tuesday, November 17th. The shares were bought at an average price of $8.35 per share, with a total value of $99,289.85. Following the completion of the purchase, the chief executive officer owned 149,891 shares in the company, valued at approximately $1,251,589.85. The trade was a 8.62% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

NeuroPace Stock Performance

Shares of NPCE stock traded up $0.23 on Tuesday, reaching $8.20. The stock had a trading volume of 684,069 shares, compared to its average volume of 219,143. The stock has a market cap of $281.42 million, a P/E ratio of -14.64 and a beta of 1.98. NeuroPace, Inc. has a 1 year low of $5.46 and a 1 year high of $19.60. The company has a debt-to-equity ratio of 4.97, a quick ratio of 3.91 and a current ratio of 4.94. The company has a 50 day simple moving average of $13.07 and a 200 day simple moving average of $14.71.

Latest NeuroPace News

These are some of the NPCE news items that stood out recently:

  • Negative Sentiment: Analyst sentiment has weakened: Wolfe Research cut its rating from Strong Buy to Hold, while Wall Street Zen moved its rating to Sell. JPMorgan downgraded the stock to Neutral and Leerink Partners to Market Perform. Wolfe Research recommendation Wall Street Zen rating
  • Negative Sentiment: A securities-law investigation is examining NeuroPace’s decision to raise its 2026 revenue outlook in August and then reduce it to $91–$92 million the following quarter. The guidance reversal may add legal and reputational uncertainty. Investigation notice
  • Negative Sentiment: Coverage also points to a third-quarter miss and lower analyst fair-value estimates, reinforcing concerns about near-term performance. Fair-value estimates after third-quarter miss

Institutional Investors Weigh In On NeuroPace

A number of hedge funds have recently modified their holdings of the business. Soleus Capital Management L.P. increased its stake in shares of NeuroPace by 10.5% in the 3rd quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company’s stock worth $44,280,000 after purchasing an additional 306,878 shares in the last quarter. Entropy Technologies LP purchased a new position in shares of NeuroPace during the 3rd quarter valued at about $146,000. Diversified Trust Co bought a new position in shares of NeuroPace in the third quarter worth approximately $153,000. First Light Asset Management LLC boosted its position in shares of NeuroPace by 16.3% in the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after purchasing an additional 401,201 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of NeuroPace in the second quarter worth $322,000. Institutional investors own 78.83% of the company’s stock.

Analyst Ratings Changes

NPCE has been the topic of several research reports. Raymond James Financial set a $21.00 target price on NeuroPace in a research report on Tuesday, September 15th. Wells Fargo & Company lowered shares of NeuroPace from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $19.00 to $9.00 in a research report on Friday. Wolfe Research lowered shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a research report on Monday. Guggenheim reiterated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. Finally, Leerink Partners downgraded shares of NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 price objective on the stock. in a report on Friday. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $13.11.

View Our Latest Stock Analysis on NPCE

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

Featured Articles

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.